ProCE Banner Activity

CME

The Impact of Cholestatic Pruritus in PBC

Text Module

Learn essential information about cholestatic pruritus in primary biliary cholangitis, including the burden of disease, patient assessment approaches, and current and emerging treatment strategies.

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: June 18, 2024

Expiration: June 17, 2025

Share

Faculty

Christopher L. Bowlus

Christopher L. Bowlus, MD

Lena Valente Professor and Chief
Division of Gastroenterology and Hepatology
University of California Davis School of Medicine
Sacramento, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This educational activity is supported by an educational grant from GlaxoSmithKline.

GlaxoSmithKline

Target Audience

This program is intended for physicians, including hepatologists and gastroenterologists, and other HCPs involved in the care of patients with PBC.

Program Learning Goal

The goal of this program is to improve learners’ knowledge and competence regarding strategies for optimizing care for patients with cholestatic pruritus secondary to PBC.

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Recognize the burden of cholestatic pruritus for patients with PBC, including the physical, emotional, and social impacts

  • Utilize tools to assess and monitor pruritus in patients with PBC

  • Develop individualized treatment plans for patients with cholestatic pruritus associated with PBC

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Christopher L. Bowlus, MD

Lena Valente Professor and Chief
Division of Gastroenterology and Hepatology
University of California Davis School of Medicine
Sacramento, California

Christopher L. Bowlus, MD: consultant/advisor/speaker: Alynylam, Amgen, ArsenalBio, ChemoMab, Cymabay, Gilead Sciences, GlaxoSmithKline, Intercept, Invea; researcher (paid to institution): Boston Scientific, Calliditas, ChemoMab, COUR, Cymabay, Gilead Sciences, GlaxoSmithKline, Hanmi, Intercept.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from June 18, 2024, through June 17, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Passport 

 

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.